Cerus Corporation to Release First Quarter 2021 Financial Results on May 4, 2021

Rhea-AI Summary

Cerus Corporation (Nasdaq: CERS) will release its Q1 2021 financial results on May 4, 2021, after market close. A conference call will follow at 4:30 P.M. ET for management to discuss the results and provide a business outlook. Interested parties can access the webcast through the company's Investor Relations page or join the call via designated phone numbers. Cerus focuses on enhancing blood safety and has developed the INTERCEPT Blood System, which is the only pathogen reduction technology with both CE mark and FDA approval for platelets and plasma.

Positive

• INTERCEPT Blood System is the only CE-marked and FDA-approved system for pathogen reduction in platelets and plasma.
• INTERCEPT red blood cell system is under regulatory review in Europe and late-stage clinical development in the US.

Negative

• None.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2021 financial results will be released on Tuesday, May 4, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8668508. The replay will be available approximately three hours after the call through May 18, 2021.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005057/en/

FAQ

When will Cerus release its Q1 2021 financial results?

Cerus Corporation will release its Q1 2021 financial results on May 4, 2021.

What time is the Cerus conference call for discussing the financial results?

The conference call will take place at 4:30 P.M. ET on May 4, 2021.

How can I access the Cerus conference call?

You can access the conference call by dialing (866) 235-9006 for U.S. calls or (631) 291-4549 for international calls.

What is the main focus of Cerus Corporation?

Cerus Corporation is dedicated to safeguarding the world’s blood supply and developing pathogen-protected blood components.

What approvals does the INTERCEPT Blood System have?

The INTERCEPT Blood System has both CE mark and FDA approval for platelet and plasma pathogen reduction.